Investing News Network

Your trusted source for investing success

Tag: patients

resources free industry report

“Trump’s victory could mean the end of Obamacare. Is right now a good time to invest in pharmaceutical stocks?”

Learn everything an investor needs to know about investing in pharmaceuticals.

Get My Free Report
Click here to download for free

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

By

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

DelMar’s new patent strengthens the Company’s control over

5 Top Biotech Stocks on the TSX Year-to-date

5 Top Biotech Stocks on the TSX Year-to-date

By

The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.

MYM Enters Into Consulting Agreement with Leading Cannabis Industry Legal Experts – International Cannabis Consultants Co.

MYM Enters Into Consulting Agreement with Leading Cannabis Industry Legal Experts – International Cannabis Consultants Co.

By

MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”)  is pleased to announce that it has entered into a consulting agreement with International Cannabis Consultants Co. (“Incanco”), leading authorities on the legal framework of cannabis legislation in Canada. Incanco’s Chief Operating Officer, John Conroy, has been a trailblazer in effecting groundbreaking

Q BioMed Announces Development Partnership With Sphaera Pharma

Q BioMed Announces Development Partnership With Sphaera Pharma

By

Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.

 “The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

By

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.

 “The opening of this

MassRoots Plans Point-of-Sale Expansion Amid Imminent Nevada Regulatory Change

MassRoots Plans Point-of-Sale Expansion Amid Imminent Nevada Regulatory Change

By

MassRoots, Inc. (OTCQB:MSRT), one of the leading technology platforms for the cannabis industry, is pleased to report it is planning to expand its point-of-sale system, MassRoots Retail (formerly known as Odava), to the Nevada cannabis market. On September 13, 2017, Nevada regulators announced all state-licensed cannabis businesses must file regulatory reports via Franwell, Inc.’s METRC system,

Cannabis café without the cannabis opening in Kelowna

Cannabis café without the cannabis opening in Kelowna

By

DOJA received media coverage from Global News, the segment showcased the health of there cannabis plants and provided a preview of the DOJA Culture Cafe under construction in Kelowna BC. The segment featured DOJA CEO Trent Kitsch,
“It’s definitely not a dispensary. The Doja Culture Café is a way for patients to

FREE Report - How Will Trump Affect Your Gold Investments? 

Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.

Click here to get your free report!

Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.

 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/delmar-pharmaceuticals-announces-issuance-new-patent-first-class-dna-targeting-agent-val-083/